Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant salvage prophylaxis after failure of conventional antiemetic therapy during moderately emetogenic chemotherapy in gastrointestinal cancer
2004-003783-30Phase 2Terminated
- Sponsor
- Technical University of Munich
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Technical University of Munich. Primary endpoints: Protection from acute and delayed nausea and emesis over days 1–5 and Protection from acute nausea and emesis on day 1. Started Feb 2005; status: terminated.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2004-003783-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003783-30.